Journal
MATRIX BIOLOGY
Volume 31, Issue 3, Pages 162-169Publisher
ELSEVIER
DOI: 10.1016/j.matbio.2012.01.005
Keywords
Thrombospondin-1; Nitric oxide; Blood pressure; Ischemia; CD47; cGMP
Categories
Funding
- National Cancer Institute, NIH
- NIH [K22CA128616, R01 HL-108954]
- American Heart Association [11BGIA7210001, 1P01HL103455-01]
- Vascular Medicine Institute
- Institute for Transfusion Medicine
- Hemophilia Center of Western PA
Ask authors/readers for more resources
Matricellular proteins play diverse roles in modulating cell behavior by engaging specific cell surface receptors and interacting with extracellular matrix proteins, secreted enzymes, and growth factors. Studies of such interactions involving thrombospondin-1 have revealed several physiological functions and roles in the pathogenesis of injury responses and cancer, but the relatively mild phenotypes of mice lacking thrombospondin-1 suggested that thrombospondin-1 would not be a central player that could be exploited therapeutically. Recent research focusing on signaling through its receptor CD47, however, has uncovered more critical roles for thrombospondin-1 in acute regulation of cardiovascular dynamics, hemostasis, immunity, and mitochondrial homeostasis. Several of these functions are mediated by potent and redundant inhibition of the canonical nitric oxide pathway. Conversely, elevated tissue thrombospondin-1 levels in major chronic diseases of aging may account for the deficient nitric oxide signaling that characterizes these diseases, and experimental therapeutics targeting CD47 show promise for treating such chronic diseases as well as acute stress conditions that are associated with elevated thrombospondin-1 expression. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available